Thus, detailed analysis of the HLA haplotypes (HLA-A/B/C), is a prerequisite in selecting the ‘best-fitting’ neoepitopes in the design of personalized cancer vaccines as well as TCR-dependent T-cell therapies (28, 71, 147, 148). Here, HLA-A is linked to cancer.